The surge of ground-breaking updates in Geographic Atrophy, along with significant advancements in developing robust biomarkers and functional endpoints, has ignited a wave of innovation in the field of ophthalmic drug development.

The 5th Dry AMD & GA Therapeutics Summit will unite 80+ biopharma stakeholders, from discovery to early clinical development, across three days of focused discussion. This summit is the definitive forum for KOLs, industry experts, and regulators to drive the next generation of dry AMD and Geographic Atrophy therapeutics forward.

Join us to explore the latest in preclinical models, optimize trial strategies, and overcome safety and regulatory challenges to supercharge your pipeline.

Event link here.